Total Payments
$31,038
2024 Payments
$728.80
Companies
32
Transactions
115
Medicare Patients
2,234
Medicare Billing
$216,662
Payment Breakdown by Category
Research$13,062 (42.1%)
Other$10,016 (32.3%)
Food & Beverage$4,694 (15.1%)
Consulting$2,832 (9.1%)
Education$432.99 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,062 | 8 | 42.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,016 | 12 | 32.3% |
| Food and Beverage | $4,694 | 74 | 15.1% |
| Consulting Fee | $2,832 | 6 | 9.1% |
| Education | $432.99 | 15 | 1.4% |
Payments by Type
General
$17,975
107 transactions
Research
$13,062
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $12,986 | 9 | $0 (2023) |
| PFIZER INC. | $8,091 | 22 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $5,388 | 12 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $776.76 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $565.46 | 7 | $0 (2023) |
| Incyte Corporation | $433.63 | 6 | $0 (2021) |
| Merck Sharp & Dohme LLC | $386.31 | 7 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $278.56 | 4 | $0 (2023) |
| BeiGene USA, Inc. | $237.36 | 3 | $0 (2023) |
| SpringWorks Therapeutics, Inc. | $165.94 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $728.80 | 15 | SpringWorks Therapeutics, Inc. ($165.94) |
| 2023 | $970.44 | 25 | BeiGene USA, Inc. ($143.74) |
| 2022 | $539.02 | 7 | Stemline Therapeutics Inc. ($122.63) |
| 2021 | $331.06 | 5 | AstraZeneca Pharmaceuticals LP ($125.00) |
| 2020 | $381.02 | 4 | Incyte Corporation ($145.10) |
| 2019 | $956.06 | 8 | Celgene Corporation ($476.00) |
| 2018 | $5,389 | 17 | Celgene Corporation ($3,717) |
| 2017 | $21,742 | 34 | Celgene Corporation ($8,774) |
All Payment Transactions
115 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: DESMOID TUMORS | ||||||
| 11/05/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $102.96 | General |
| 11/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $31.05 | General |
| Category: Oncology | ||||||
| 10/16/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: DESMOID TUMORS | ||||||
| 09/03/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $88.25 | General |
| Category: Oncology | ||||||
| 09/03/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2024 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $79.03 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: ONCOLOGY | ||||||
| 04/02/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $115.98 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/05/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $121.80 | General |
| Category: DESMOID TUMORS | ||||||
| 01/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: Oncology | ||||||
| 11/15/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Oncology | ||||||
| 11/07/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $69.75 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/17/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $14.87 | General |
| Category: Oncology | ||||||
| 09/08/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.93 | General |
| 09/07/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: CELLT | ||||||
| 08/17/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Oncology | ||||||
| 08/01/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $121.85 | General |
| 07/25/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Oncology | ||||||
| 07/20/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $14.42 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABI-007-NSCL-003 | Celgene Corporation | $6,107 | 1 |
| AZA-ST-001 - A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors | Celgene Corporation | $3,444 | 1 |
| AZA-ST-001 | Celgene Corporation | $2,533 | 1 |
| A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects (CC-486-CAGEN-001) | Celgene Corporation | $476.00 | 1 |
| ABI-007-NSCL-003 - A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in su | Celgene Corporation | $273.00 | 1 |
| A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $95.00 | 1 |
| An Investigational Immunotherapy Study of BMS 986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | E.R. Squibb & Sons, L.L.C. | $90.00 | 1 |
| TAS-120 | Taiho Oncology, Inc. | $44.41 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 427 | 744 | $118,919 | $51,516 |
| 2022 | 5 | 512 | 779 | $132,991 | $56,222 |
| 2021 | 9 | 662 | 925 | $149,026 | $65,259 |
| 2020 | 8 | 633 | 987 | $125,468 | $43,665 |
Total Patients
2,234
Total Services
3,435
Medicare Billing
$216,662
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 320 | 585 | $92,259 | $39,654 | 43.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 63 | $13,938 | $6,617 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 49 | 77 | $7,820 | $3,437 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 19 | 19 | $4,902 | $1,808 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 320 | 511 | $79,716 | $33,055 | 41.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 73 | 128 | $27,904 | $13,042 | 46.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 41 | 41 | $10,578 | $4,063 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 57 | 78 | $7,800 | $3,261 | 41.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $6,993 | $2,801 | 40.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 306 | 466 | $72,696 | $33,914 | 46.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 69 | 121 | $26,378 | $13,073 | 49.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 122 | 152 | $15,200 | $5,656 | 37.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 41 | 41 | $10,578 | $4,033 | 38.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 44 | $9,416 | $3,486 | 37.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $4,329 | $1,853 | 42.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 17 | 17 | $4,709 | $1,588 | 33.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 58 | 58 | $3,770 | $884.03 | 23.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 13 | 13 | $1,950 | $773.52 | 39.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 345 | 547 | $54,700 | $18,176 | 33.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 114 | 204 | $31,824 | $11,446 | 36.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 45 | 90 | $13,410 | $5,013 | 37.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 35 | 35 | $9,030 | $3,347 | 37.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 20 | 20 | $5,540 | $2,127 | 38.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 17 | 21 | $4,567 | $1,643 | 36.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 22 | 22 | $3,300 | $1,073 | 32.5% |
About Dr. William Edenfield, MD
Dr. William Edenfield, MD is a Hematology & Oncology healthcare provider based in Greenville, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1851396295.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Edenfield, MD has received a total of $31,038 in payments from pharmaceutical and medical device companies, with $728.80 received in 2024. These payments were reported across 115 transactions from 32 companies. The most common payment nature is "" ($13,062).
As a Medicare-enrolled provider, Edenfield has provided services to 2,234 Medicare beneficiaries, totaling 3,435 services with total Medicare billing of $216,662. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Greenville, SC
- Active Since 06/14/2005
- Last Updated 05/20/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851396295
Products in Payments
- XALKORI (Drug) $7,460
- CC-486 (Drug) $6,453
- Abraxane (Drug) $6,380
- Treanda (Drug) $2,368
- TREANDA (Drug) $651.56
- KEYTRUDA (Biological) $386.31
- BRUKINSA (Drug) $237.36
- IMFINZI (Biological) $220.54
- OGSIVEO (Drug) $165.94
- INLYTA (Drug) $134.61
- Revlimid (Drug) $133.99
- TAGRISSO (Drug) $125.00
- KRAZATI (Drug) $121.84
- CALQUENCE (Drug) $121.55
- Somatuline Depot (Drug) $119.00
- Rezlidhia (Drug) $115.98
- ADCETRIS (Biological) $112.30
- IMBRUVICA (Drug) $102.13
- Cabometyx (Drug) $98.82
- Onivyde (Drug) $89.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Greenville
Dr. Suzanne Fanning, D.o, D.O
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Joe Stephenson, Md, MD
Hematology & Oncology — Payments: $137,970
Hematology & Oncology $137,970
Dr. Paul Walker, M.d, M.D
Hematology & Oncology — Payments: $66,454
Hematology & Oncology $66,454
Dr. Darla Liles, Md, MD
Hematology & Oncology — Payments: $49,052
Hematology & Oncology $49,052
Dr. Raid Aljumaily, M.d, M.D
Hematology & Oncology — Payments: $21,498
Hematology & Oncology $21,498
Dr. Jay Walls, Md, MD
Hematology & Oncology — Payments: $13,590
Hematology & Oncology $13,590